Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-α

Digestive Diseases and Sciences

Volumn 44, Issue 5, 1999, Pages 1027-1033

  Ninomiya, Toshiaki ^b   Yoon, Seitetsu ^a   Sugano, Masahiko ^b   Kumon, Yoshiko ^b   Seo, Yasushi ^b   Shimizu, Keiichi ^b   Nagano, Hidenobu ^b   Kasuga, Masato ^b   Hayashi, Yoshitake ^b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Branched chain amino acids; Chronic hepatitis C; HAI score; Interferon ; Liver fibrosis; Molar ratio; Tyrosine

Indexed keywords

ALPHA INTERFERON; AROMATIC AMINO ACID; BRANCHED CHAIN AMINO ACID; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TYROSINE;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; ENZYME CHEMISTRY; FEMALE; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER FUNCTION; LIVER HISTOLOGY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STAGING;

ADULT; AGED; AMINO ACIDS, BRANCHED-CHAIN; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TYROSINE;

EID: 0032964905     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026629202076     Document Type: Article

References (30)

1. Fischer JE, Yoshimura N, Aguirre A, James JH, Cummings MG, Abel RM, Deindoerfer F: Plasma amino acids in patients with hepatic encephalopathy: Effects of amino acid infusions. Am J Surg 127:40-47, 1974
2. Fischer JE, Funovics JM, Aguirre A, James JH, Keane JM, Wesdrop RIC, Yoshimura N, Westman T: The role of plasma amino acids in hepatic encephalopathy. Surgery 78:276-290, 1975
3. Soeters PB, Fischer JE: Insulin, glucagon amino acid imbalance, and hepatic encephalopathy. Lancet ii;880-882, 1976
4. Munro HN, Fernstrom JD, Wurtman RJ: Insulin, plasma amino acid imbalance, and hepatic coma. Lancet i:722-723, 1975
5. Morgan MY, Marshall AW, Milson JP, Sherlock S: Plasma amino-acid patterns in the liver disease. Gut 23:362-370, 1982
6. Morgan MY, Milson JP, Sherlock S: Plasma ratio of valine, leucine and isoleucine to phyenylalanine and tyrosine in liver disease. Gut 19:1068-1073, 1978
7. McCullough AJ, Albert JC, Jones JD, Go VLW: The nature and prognostic significance of serial amino acid determinations in severe chronic active liver disease. Gastroenterology 81:645-652, 1981
8. Shiels MT, Czaja AJ, Ludwig J, McCullough AJ, Jones JD, Go VLW: Diagnostic and prognostic implications of plasma ammo acid determinations in chronic active hepatitis. Dig Dis Sci 9:819-823, 1985
9. Kano T, Nagaki M, Takahashi T, Ohnishi H, Saitoh K, Kimura K, Muto Y: Plasma free amino acid pattern in chronic hepatitis as a sensitive and prognostic index. Gastroenterol Jpn 26:344-349, 1991
10. Azuma Y, Masato M, Kuwabara Y, Nakajima T, Taniguchi K, Kanno T: Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic disease, and its clinical usefulness. Clin Chem 35:1399-1403, 1989
11. Shimizu H, Taniguchi K, Sugiyama M, Kanno T: Rapid enzymatic analysis of plasma for tyrosine. Clin Chem 36:32-35, 1990
12. Nakamura T, Mori M, Yoshida T, Murakami N, Kato T, Sugihara J, Saito K, Moriwaki H, Tomita E, Muto Y, Abe A, Nishimura T, Noma A: Enzymatic determination of a molar ratio of free branched-chain amino acids to tyrosine (BTR) and its clinical significance in plasma of patients with various liver diseases. Jpn J Clin Parhol 37:911-917, 1989
13. Abe A, Okuno M, Noma A, Imamine T, Nakamura T, Muto Y: Enzymatic assay of tyrosine and branched-chain amino acids in plasma and its application to liver disease. Jpn J Clin Chem 19:124-130, 1990
14. Tameda Yukihiko, Ooi Kinue, Kosaka Y, Takase K, Itoh N: Enzymatic assay of the ratio of scrum branched chain amino acid to tyrosine and its clinical significance in patients with various liver diseases. Mie Med J 43:243-251, 1993
15. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24:778-789, 1996
16. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J: Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. J Hepatol 17:390-396, 1993
17. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud JA: Interferon-alpha (2b) therapy reduces liver fibrosis in chronic non-A hepatitis non-B hepatitis. A quantitative histological evaluation. Hepatology 18:1344-1349, 1993
18. Guechot J, Loria A, Serfaty L, Giral P, Gibudeau J, Poupon R: Serum hyaluronan as a maker of liver fibrosis in chronic viral hepatitis C: Effect of α-interferon therapy. J Hepatol 22:22-26, 1995
19. Hiramatu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, Fusamoto H, Kamada T: Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22:135-142, 1995
20. Ninomiya T, Yoon S, Hayashi Y, Sugano M, Kumon Y, Seo Y, Shimizu K, Kasuga M: J Gastroenterol Hepatol 13:68-74, 1998
21. Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, 1995
22. Sugiyama M, Kanno T, Ohkubo A, Muto Y, Murata K, Ueno Y: The clinical usefulness of the molar ratio of branched-chain amino acids to tyrosine (BTR) in discriminating stage of chronic liver disease. Jpn J Clin Pathol 40:673-678, 1992
23. Davis GL, Balart LA, Schiff ER, Lindsay D, Bodenheimer HC, Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DA, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: Hepatitis interventional therapy group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
24. Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
25. Jimenez SA, Freundlich B, Rosenbloom J: Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 10:795-800, 1984
26. Berman B, Duncan MR: Short term keloid treatment in vivo with human interferon alpha-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Derematol 21:694-702, 1989
27. Tutumi Y, Kakumu S, Yoshioka K, Arao M, Inoue M, Wakita T: Effects of various cytokines on collagen synthesis by normal rat hepatocytes in primary cultures and fibroblasts. Digestion 44:191-199, 1989
28. 1 and α in chronic liver disease. Effects of interferon alpha therapy. N Engl J Med 324:933-940, 1991
29. Ali FM, Ansley J, Faraj BA: Studies of the influence of portacaval shunt on the metabolism of tyrosine. J Pharmacol Exp Ther 214:546-553, 1980
30. Anderson SM, Salaspuro M, Ohisalo JJ: Metabolic basis of hypertyrosinemia in liver disease. Gastroenterology 82:554-557, 1982